Symyx Technologies (Symyx) has joined SAFE-BioPharma Association. The membership enables Symyx to implement the SAFE-BioPharma digital signature standard for records signing to safe-guard critical scientific data.
The membership also enables Symyx to participate in SAFE-BioPharma working groups to further secure the electronic laboratory environment. Reportedly, Symyx customers can utilise SAFE-BioPharma digital signature within Symyx Notebook, an enterprise electronic lab notebook (ELN).
Symyx Notebook enables scientists to plan, execute and analyse experiments across the spectrum of research, development and analytical QC labs while providing data and document workflow transparency to life sciences and chemicals businesses.
Aditionally, Symyx Notebook experimental entries provide key documentation for the intellectual properties of Symyx’s pharmaceutical and biotechnology customers, establishing the date of record for invention which is vital to patent claims and patent defense litigation.
The Symyx Notebook platform also enables scientists to connect with their existing laboratory instrumentation and software tools to gain compliance protection without redeveloping operational business practices.
Mollie Shields-Uehling, president and CEO of SAFE-BioPharma Association, said: Applying a SAFE-BioPharma digital signature to mission-critical documents establishes a robust and defensible record of invention for R&D companies needing to protect and defend their IP. Our industry-standard protocol helps mitigate the legal, regulatory and business risks associated with electronic transactions, while facilitating interoperability between disparate information systems.